A decision process for drug discovery in retinoblastoma Journal Article
| Authors: | Cancela, M. B.; Zugbi, S.; Winter, U.; Martinez, A. L.; Sampor, C.; Sgroi, M.; Francis, J. H.; Garippa, R.; Abramson, D. H.; Chantada, G.; Schaiquevich, P. |
| Article Title: | A decision process for drug discovery in retinoblastoma |
| Abstract: | Intraocular retinoblastoma treatment has changed radically over the last decade, leading to a notable improvement in ocular survival. However, eyes that relapse remain difficult to treat, as few alternative active drugs are available. More challenging is the scenario of central nervous system (CNS) metastasis, in which almost no advancements have been made. Both clinical scenarios represent an urgent need for new drugs. Using an integrated multidisciplinary approach, we developed a decision process for prioritizing drug selection for local (intravitreal [IVi], intrathecal/intraventricular [IT/IVt]), systemic, or intra-arterial chemotherapy (IAC) treatment by means of high-throughput pharmacological screening of primary cells from two patients with intraocular tumor and CNS metastasis and a thorough database search to identify clinical and biopharmaceutical data. This process identified 169 compounds to be cytotoxic; only 8 are FDA-approved, lack serious toxicities and available for IVi administration. Four of these agents could also be delivered by IT/IVt. Twelve FDA-approved drugs were identified for systemic delivery as they are able to cross the blood-brain barrier and lack serious adverse events; four drugs are of oral usage and six compounds that lack vesicant or neurotoxicity could be delivered by IAC. We also identified promising compounds in preliminary phases of drug development including inhibitors of survivin, antiapoptotic Bcl-2 family proteins, methyltransferase, and kinesin proteins. This systematic approach may be applied more broadly to prioritize drugs to be repurposed or to identify novel hits for use in retinoblastoma treatment. © 2020, Springer Science+Business Media, LLC, part of Springer Nature. |
| Keywords: | metastasis; retinoblastoma; intraocular; decision process; high-throughput drug screening |
| Journal Title: | Investigational New Drugs |
| Volume: | 39 |
| Issue: | 2 |
| ISSN: | 0167-6997 |
| Publisher: | Springer |
| Date Published: | 2021-04-01 |
| Start Page: | 426 |
| End Page: | 441 |
| Language: | English |
| DOI: | 10.1007/s10637-020-01030-0 |
| PUBMED: | 33200242 |
| PROVIDER: | scopus |
| PMCID: | PMC8488950 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 April 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work